Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 11-arm NCT06491446

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts

Sponsor: Antiva Biosciences

Conditions Human Papillomavirus Infection

Interventions ABI-2280

Updated 5 times since 2024 Last updated: Feb 16, 2026 Started: Mar 27, 2024 Primary completion: Oct 16, 2025 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Human Papillomavirus Infection, this trial is ongoing. The trial is conducted by Antiva Biosciences and has accumulated 5 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Antiva Biosciences

Data source: Antiva Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Birkenhead, New Zealand , Camberwell, Australia , Cuauhtémoc, Mexico , Darlinghurst, Australia , Dunedin, New Zealand , Eldoret, Kenya , Hastings, New Zealand , Kisii, Kenya , Kisumu, Kenya and 13 more locations